Abstract Isolated growth hormone deficiency (IGHD) represents conditions of GH deficiency that are not necessarily associated with other pituitary hormone deficiencies or with an organic lesion. Three sub-categories of IGHD have been clinically identified (IGHD types 1-3), and IGHD type 1 has been further separated into IGHD types 1a and b. However, this clinical sub-categorization of IGHD may need reconsideration due to the recent identification of molecular heterogeneity within each sub-type of IGHD. In a small number of children with IGHD, defects in the GH, GH-releasing hormone receptor (GHRH-R), and GH1 genes have been identified. In most cases, no cause for IGHD can be identified; however, the proportion of idiopathic IGHD cases may be decreasing due to identification of causative factors. The phenotype of IGHD is variable depending in part on the underlying genetic disorders in the affected individuals. Several studies have focused on the usefulness of MRI findings in patients with GHD but anatomic abnormalities of the pituitary gland are variable. We review current studies and the clinical, biochemical, and molecular features described for different groups of affected individuals with IGHD.
Introduction
Isolated growth hormone deficiency (IGHD) refers to conditions associated with childhood growth failure due to lack of growth hormone (GH) action, and not necessarily associated with other pituitary hormone deficiencies or with an organic lesion other than a congenital structural abnormality. The incidence of IGHD is estimated to be 1/3,480-1/10,000 live births [1] [2] [3] [4] .
While the majority of IGHD cases are sporadic and thought to be caused by in utero, natal or postnatal hypothalamic or pituitary insults, anatomic abnormalities are found in only 12% of such patients examined by magnetic resonance imaging (MRI) [5] . In the majority of children with IGHD no cause can be identified; this group is often referred to as idiopathic GH deficiency or idiopathic IGHD. However, within this group of idiopathic cases, there is increasing recognition of associated genetic defects. General clinical findings in patients with IGHD may include frontal bossing, immature facies for chronological age, poor development of the nasal bridge, delayed secondary dentition, and a high-pitched voice [6] . In infants closure of the anterior fontanel may be delayed and male infants may present with micropenis. Puberty may be delayed until the late teens, but eventual sexual maturation and fertility are usually normal.
IGHD has been classified on the basis of clinical characteristics, including inheritance patterns and GH secretion, into three types. Type 1 is further separated into two sub-types. This classification system has no intrinsic relationship to disease causation, but has been useful for clinical investigations of IGHD.
IGHD type 1, characterized by autosomal recessive transmission, is further separated into sub-types 1a and b. IGHD type 1a is the most severe form of IGHD. Patients with IGHD type 1a may have decreased birth length, and typically present with neonatal hypoglycemia, prolonged jaundice associated with severe postnatal growth retardation and characteristic facies that can be apparent by 6 months of age [7] [8] [9] [10] . Patients with IGHD type 1a lack detectable serum GH, have a strong initial response to therapy with GH, but often develop anti-GH neutralizing antibodies with continued GH replacement. The phenotype of IGHD type 1b is milder than that of IGHD type 1a. Serum GH levels after provocative stimuli are low, but detectable. Affected individuals usually respond well to GH therapy and do not develop neutralizing antibodies.
IGHD type 2, often cited as the most common form of IGHD exclusive of idiopathic GHD, is inherited in an autosomal dominant pattern. Many cases of IGHD type 2 are associated with GH1 gene mutations, as described below. IGHD type 3, is an X-linked recessive disorder with a highly variable phenotype. Some individuals have an associated X-linked agammaglobulinemia [11, 12] . It has been suggested that multiple loci may be involved in the etiology of IGHD type 3 [13] .
The clinical classification system for IGHD may have limited future utility since there is increasing recognition of identifiable causes for IGHD. About 5-30% of patients with IGHD are found to have affected first-degree relatives, suggesting genetic causes [4, 14] . As described below, defects in the gene for growth hormone releasing hormone receptor (GHRH-R) or in the GH1 gene have been identified in an increasing number of individuals with IGHD.
GHRHR gene mutations
The GHRH receptor (GHRHR) is a G-protein-coupled receptor with seven trans-membrane domains, and is found predominantly in the pituitary gland. The human GHRHR gene is 15 kb in size and divided into 13 exons separated by variably sized introns; GHRHR protein is encoded by a 1.3 kb cDNA [15] [16] [17] [18] .
The first GHRH-R mutation associated with IGHD was reported by Wajnrajach et al. [19] , who described two children in a consanguineous Indian Muslim family with a nonsense mutation that introduced a stop codon at position 72 (E72X). The same mutation was subsequently identified in a apparently unrelated kindred from Sri Lanka [20] [25] [26] [27] . For instance, in an extensive Brazilian kindred in which several members have severe IGHD, a novel homozygous donor splice mutation (G to A at position +1) in intron 1 of the GHRH-R gene was identified. This mutation disrupts the highly conserved consensus GT of the 5 0 -donor splice site, generating a truncated GHRH receptor [13, 28] . Recently, a novel GHRHR missense mutation in exon 11 (R357C) was described in two highly consanguineous Israeli Arab families; all affected individuals had a good clinical response to GH treatment [29] .
Early growth failure, proportionate short stature, highpitched voice, and increased abdominal fat accumulation are typical clinical characteristics of patients with GHRHR mutations. Subjects with homozygous mutations in GHRHR attain an adult height that ranges between 105 and 135 cm, or -4.5 to -8.6 SD below normal [4] . All affected individuals showed markedly reduced or undetectable serum concentrations of GH in response to GH secretagogues, as well as very low-serum concentrations of IGF-I, IGFBP-3, and ALS throughout life [28] .
The typical phenotype has an unfavorable cardiovascular risk profile, including increased low-density lipoprotein and total cholesterol, elevated C-reactive protein, increased blood pressure, and abdominal obesity. However, a recent study in individuals with GHRHR mutations found no evidence of premature atherosclerosis or premature myocardial ischemia [30] .
GH1 gene defects
GH is a 191-amino-acid protein encoded by the GH1 gene, which is a member of the GH gene family (GH1, GH2, CSHP1, CSH1 CSH2) clustering on the long arm of chromosome 17 (17q22-24). GH1 consists of five exons and four introns [7] [8] [9] [10] . Published estimates are that 10-15% of subjects with severe IGHD (height [4.5 SD below the mean) have GH1 gene deletions [11, [31] [32] [33] [34] . However, this estimate of frequency may conceal ethnic or geographic differences as well as differences in patient selection criteria between studies. For example Wagner et al. [11] reported ethnic and geographic differences in GH1 gene deletion frequencies in their study. They found that the absolute frequency of GH1 gene deletions was 8.7% in Northern Europe, 11.8% Mediterranean countries, and 18.7% in Asia. However, the most striking finding was the low-frequency rate (2/119, or 1.7%) of GH1 gene mutations associated with the most common phenotype of IGHD type 1b.
On the other hand, in individuals with IGHD type 2, several heterozygous mutations have been reported at the intron 3 donor splice site or in intron 3 of the GH1 gene, causing aberrant GH messenger RNA splicing and deletion of exon 3 and, consequently, amino acid residues 32 through 71 in the mature GH protein [35] . This mutant GH exerts a dominant negative effect on the accumulation of wild-type GH in vitro [36, 37] . In addition to the above-described splice site mutations, several missense mutations have been reported [38, 39] . However, Fintini et al. [40] showed that GH1 mutations were absent in 16.6% of the families with IGHD type 2 raising the possibility that mutations in other gene(s) may be involved in this disorder.
Patients with IGHD type 2 due to GH1 mutations have low but detectable GH levels and respond well to exogenous GH therapy. Analysis of clinical data of 16 familial cases and 1 sporadic case with IGHD type 2 [39] showed that the onset of growth failure was earlier and the degree was more severe in affected children with GH1 splice site mutations compared with GH1 missense mutations. In addition, the severity of the phenotype was variable, even within the same family. Most of the children were lean at diagnosis and pre-treatment serum IGF-I and IGF-binding protein-3 (IGFBP-3) levels were decreased. The height of the adenohypophysis studied by MRI was normal in two affected children and mildly decreased in two others. The five affected adults had final height SD scores between -1.8 and -4.5 SD (median, -3.6 SD), centripetal obesity, and muscular hypotrophy. Affected individuals presented with variable phenotype despite apparently homogeneous hormone data consistent with severe GH and IGF-I deficiencies. The age at diagnosis and the degree of short stature were variable, even in members of the same family. This variability suggests that the onset and predominance of GH-dependent growth during infancy are individually different and modified by nutritional status and other as yet unknown factors [39] .
Subjects presenting with a splice site mutation leading to a skipping of exon 3 are more likely to present with other pituitary hormone deficiencies during follow-up [9] . The development of multiple hormonal deficiencies is not age dependent, and there is a clear variability in onset, severity, and progression, even within the same family.
Bio-inactive GH
The concept of bio-inactive GH was first described by Kowarski et al. [41] , based on the observation of two children with short stature with normal to high-immunoreactive serum GH levels associated with low-serum concentrations of IGF-I.
More recently, Takahashi et al. [42] described two unrelated Japanese patients with mis-sense mutations in the GH1 gene. The first case was a 3-year-old girl with nonconsanguineous parents who had a height of -3.6 SD and bone age delayed by 1.5 years. On physical examination, she had a prominent forehead, hypoplastic nasal bridge, and normal body proportions. Her serum IGF-I level was low and her GH levels increased upon pharmacological provocation. A heterozygous single-base substitution of glycine for aspartic acid at codon 112 in exon 4 (D112G) of the GH1 gene was identified. This mutation causes production of a mutant GH with impaired binding to dimerized GH receptor and consequent bio-inactivity. After treatment with GH, serum IGF-I concentration increased and linear growth rate was improved. This case was the first example of bio-inactive GH syndrome with a demonstrated molecular mechanism [42, 43] .
The second case was a boy who presented at the age of 4.9 years with a height of -6.1 SD, bone age of 2 years, high-basal serum GH hormone concentrations, low-serum IGF-I levels, and increased GH on provocation testing. A GH1 gene mutation was identified (R77C). Initially, GH treatment improved his IGF-I concentration and linear growth but this effect declined dramatically after 1 year of therapy [43, 44] .
Lewis et al. [45, 46] reported five heterozygous defects of the GH1 gene in four different individuals and Ile179-Met was one of the two novel defects identified. Ile179Met was found to induce normal phosphorylation of the STAT5 GH1 promoter, but its ability to activate ERK was reduced to 50% of normal. Since this variant was identified in a child with short stature, this case provides evidence that the ERK pathway plays a role in mediating some of the growth-promoting effects of GH.
A recent study by Besson et al. [47] , demonstrated that the mutant GH (C53S) is bio-inactive at physiological concentrations. They described a homozygous missense mutation, C53S, in the GH1 gene in a Serbian patient who at the age of 9 years presented with severe short stature (-3.6 SD). The bio-inactivity of GH (C53S) is due to lower affinity for the GH receptor, presumably caused by the 
Idiopathic IGHD
Currently, most cases of isolated IGHD are considered to be idiopathic. In some instances IGHD and idiopathic short stature (ISS) can be difficult to distinguish clinically. Wit et al. [48] reported data on final height of untreated and treated children with IGHD and ISS. Untreated IGHD with spontaneous puberty reached a mean final height of -4.7 SD, compared to -3.1 SD if puberty was induced. IGHD with GH treatment and spontaneous puberty had a final height SDS of -2.8 SD; as compared to -1.6 for induced puberty. The mean gain in final height SDS is therefore estimated at 1.5-2.0 SD in average cases, and 3.5 SD in extreme cases of IGHD treated with GH. Preliminary data suggest that with GH treatment, final height may approach target height. In untreated boys with ISS the mean final height was 2-5 cm lower than that predicted before puberty, whereas in girls it was almost equal to the prediction. After GH treatment the mean final height was 0.4-3.0 cm higher than the predicted adult height, which results in an average net gain in final height SDS of *0.5-0.8 (3-5 cm). It is possible to achieve final height within the midparental height range in patients with idiopathic GHD treated from an early age with GH, but absolute height outcomes remain in the lower part of the normal range [49] . Clinical features associated with idiopathic IGHD are variable, and include breech position at birth, neonatal or early onset hypoglycemia, prolonged or severe neonatal jaundice, micropenis, and single central incisor [50, 51] . Recent MRI observations in children with idiopathic GHD suggested a positive relationship between the volume of the adenohypophysis and secretory GH capacity [52] .
Neuroimaging
Non-invasive brain imaging techniques have brought new knowledge concerning the etiology and the possible pathophysiology of IGHD. Brain MRI is the most sensitive diagnostic technique for definition of the anatomy of the hypothalamic-pituitary region, and is useful for characterizing solid components as well as developmental defects of the hypothalamic-pituitary region [53] .
In confirmed IGHD with or without known genetic defects, the following features should be recorded from the MRI (ideally performed with 2 mm slices; with and without contrast): pituitary dimensions and/or volume, anatomy of the stalk, and position of the posterior pituitary. Such features may be useful in characterizing the anatomy of the gland. However, it is recognized that additional normative data are required to improve the quality of this assessment in children [54] .
In MRI studies reported by Hamilton et al. [52] in children with IGHD, the diagnoses were: normal pituitary gland (20%), small anterior pituitary with normal posterior pituitary (10%), and small anterior pituitary with ectopic posterior pituitary (70%). In addition, other CNS mid-line abnormalities included optic nerve hypoplasia (10%), Chiari I malformation (20%), and medially deviated carotid artery (45%).
Hypoplasia of the anterior pituitary on MRI in individuals affected by non-sense mutations in the GHRHR gene have been reported by Netchine et al. [17] and Murray et al. [55] in two siblings (age 9 and 10 years) and in four related patients (22-29-year old), respectively. These results are also consistent with those reported by Carakushansky et al. [27] , who described MRI findings in two male siblings from consanguineous parents, both affected children had a missense mutation in the GHRHR gene. However, a study in Brazil [56] reported both small and normal pituitaries among four patients (10-25-year old) belonging to three different families and carrying two different mutations in the GHRHR gene. A common feature in all patients with GHRHR mutations was a normal pituitary stalk and normal posterior lobe. Patients with hereditary IGHD usually have a pituitary gland of normal height, with normal appearance of the neurohypophysis and pituitary stalk [56, 57] .
Therefore, anatomic abnormalities of the pituitary gland are relatively common in cases of IGHD. Published studies have reported neuroimaging findings ranging from a normal pituitary gland to an ectopic neurohypophysis, abnormal pituitary stalk, hypoplastic or absent adenohypophysis, mid-line malformations, septo-optic dysplasia, and Chiari I malformation [20, 27, 51, 52, [55] [56] [57] [58] [59] [60] [61] [62] . These findings indicate the importance of MRI imaging in the evaluation and classification of patients with IGHD.
Summary
Clinical heterogeneity is characteristic of IGHD (Tables 1,  2) . Neuroimaging and genetic analysis are useful tools in the diagnostic evaluation of patients with IGHD. For example, a child with IGHD, severe short stature and a normal adenohypophysis as determined by MRI may deserve evaluation for GH1 splice site and missense mutations, remembering that children with GH1 splice site mutations have an earlier onset and a more severe growth failure than those with GH1 missense mutations. Patients with IGHD type 2 may develop other pituitary hormone deficits over time, emphasizing the importance of maintaining careful clinical and biochemical vigilance.
With the exception of patients with IGHD type 1a, final height within the mid-parental height range can be achieved if these patients are identified at an early age and appropriate GH dosing is used. Children with deletion of the GH gene as a cause for IGHD type 1a can have a good initial clinical response to GH therapy, but often develop GH neutralizing antibodies; in these cases, treatment with rhIGF-I alone or rhIGF-I/rhIGFBP-3 complex could be effective.
Although the cause of most cases of IGHD remain undefined, or idiopathic, continuing investigations in this field appear likely to reveal molecular causes for many, if not most, cases of IGHD associated with severe growth failure. 
